Today: 29 January 2026
Subscribe
Browse Category

Pharma Industry News 15 October 2025 - 4 November 2025

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Company Profile & Background Scienture Holdings, Inc. is a tiny specialty pharmaceutical company focused on developing and commercializing novel formulations that address unmet needs in healthcare Globenewswire Globenewswire. The company’s roots trace back to a 2024 merger with TRxADE Health, a drug marketplace business – after which the combined entity rebranded as Scienture (NASDAQ: SCNX) Nasdaq. In early 2025, management…
4 November 2025
····
Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Stock Price and Recent Performance Year-to-date chart of Evoke Pharma (EVOK) stock through early November 2025. Shares were volatile throughout 2025, and the Q4 acquisition announcement (right end of chart) triggered a dramatic spike to new highs, bringing the stock roughly back to breakeven for the year Tipranks. Evoke Pharma’s stock has experienced extreme volatility in recent weeks. After trading…
4 November 2025
····
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir Surges on Strong AI-Fueled Earnings Palantir Technologies delivered a record third quarter, easily topping analyst expectations on both revenue and profit. The company’s revenue jumped 63% year-over-year to $1.18 billion, with adjusted earnings of $0.21 per share – well above estimates of about $0.17 Investopedia. CEO Alex Karp credited booming demand for Palantir’s Artificial Intelligence Platform, especially among commercial customers.…
4 November 2025
····
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news…
3 November 2025
···
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Technical Analysis – Levels to Watch From a technical perspective, Pfizer’s stock has been basing in the low-to-mid $20s and has yet to break out of its longer-term downtrend. The 52-week range is roughly $20.92 to $30.43 ts2.tech, and the late-September rally stalled out near the upper-$20s – a zone that now acts as an overhead resistance (around $26–$27). Notably,…
1 November 2025
···
Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

Intellia Stock Crashes on CRISPR Trial Safety Scare – What’s Next After 45% Plunge?

NTLA Stock Plunges on Trial Halt Intellia’s stock implosion began early Monday after the biotech stunned investors with news of a trial pause. Before the market opened on Oct. 27, the Cambridge, MA-based company announced it had temporarily halted patient dosing and screening in two late-stage trials of its in vivo CRISPR therapy NTLA-2001 due to a serious adverse event ts2.tech. The…
28 October 2025
···
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Breakthrough Trial Results in Rare Bone Cancer Inhibrx’s lead drug, ozekibart, achieved a landmark win in its ChonDRAgon trial for advanced conventional chondrosarcoma. This rare bone cancer has no approved systemic therapies, so the positive data are significant. According to the company and press accounts, the trial met its primary endpoint with a statistically significant jump in progression-free survival (PFS)…
24 October 2025
···
Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year Marketbeat – following stronger-than-expected Q2 results (earnings beat and record revenue). However, on Oct 22 the company’s interim cystic fibrosis data triggered a dramatic sell-off. Investing.com reported that…
22 October 2025
····
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at a $1.64 closing price – a stunning +248% one-day gain Investing. The prior day, RANI had closed at just $0.47,…
20 October 2025
····
Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

Disc Medicine (IRON) Stock Soars on FDA Fast-Track News as Analysts Boost Targets

FDA Voucher Ignites IRON Stock Rally Disc Medicine’s stock price (NASDAQ: IRON) spiked dramatically in mid-October 2025 after news of the FDA voucher, vaulting from the mid-$70s to the low-$90s in a single day Gurufocus. On Friday (Oct. 17), IRON opened around $85 and surged to an intraday high of $92.50 before closing at $93.00, marking a ~25% jump on…
17 October 2025
····
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Novo Nordisk Licensing Deal Sparks Rally On Oct. 15, Novo Nordisk (NYSE: NVO) and Omeros announced a landmark deal licensing zaltenibart (OMS906), Omeros’s experimental MASP-3 inhibitor for rare blood/kidney diseases Omeros. Under the agreement, Novo pays $340M upfront and can pay up to $2.1 billion in total milestones and royalties for exclusive global rights Omeros Reuters. Reuters reports that Omeros…
15 October 2025
····
1 … 5 6 7 8

Stock Market Today

  • Corn Futures Rise Amid Weaker Dollar and Wheat Gains
    January 29, 2026, 1:01 AM EST. Corn futures advanced Wednesday, rising 3 to 4 ¼ cents amid strength from wheat markets and a weaker U.S. Dollar index. The national average Cash Corn price increased 4 ½ cents to $3.944. Data from the Energy Information Administration showed ethanol production dropped 5,000 barrels per day last week to 1.114 million bpd, while stocks declined by 339,000 barrels to 25.4 million barrels. Ethanol exports decreased 61,000 bpd, but refiner inputs rose by 31,000 bpd. President Trump expressed support for year-round E-15 ethanol availability. Traders await Thursday's Export Sales figures, anticipating 2025/26 corn bookings between 1 to 2.5 million metric tons.
Go toTop